LIN Ying, SHAO Nan, REN Chong-yang. Addition of Bevacizumab to Endocrine Therapy as First-Line Treatment for Advanced Breast Cancer Cannot Increase in Survival[J]. Journal of Evidence-Based Medicine, 2015, 15(3): 141-143. DOI: 10.3969/j.issn.1671-5144.2015.03.007
|
Citation:
|
LIN Ying, SHAO Nan, REN Chong-yang. Addition of Bevacizumab to Endocrine Therapy as First-Line Treatment for Advanced Breast Cancer Cannot Increase in Survival[J]. Journal of Evidence-Based Medicine, 2015, 15(3): 141-143. DOI: 10.3969/j.issn.1671-5144.2015.03.007
|
LIN Ying, SHAO Nan, REN Chong-yang. Addition of Bevacizumab to Endocrine Therapy as First-Line Treatment for Advanced Breast Cancer Cannot Increase in Survival[J]. Journal of Evidence-Based Medicine, 2015, 15(3): 141-143. DOI: 10.3969/j.issn.1671-5144.2015.03.007
|
Citation:
|
LIN Ying, SHAO Nan, REN Chong-yang. Addition of Bevacizumab to Endocrine Therapy as First-Line Treatment for Advanced Breast Cancer Cannot Increase in Survival[J]. Journal of Evidence-Based Medicine, 2015, 15(3): 141-143. DOI: 10.3969/j.issn.1671-5144.2015.03.007
|
DownLoad: